Bibliography
- SCHWARDT O, KOLB H, ERNST B: Drug discovery today. Curr. Top. Med. Chem. (2003) 3:1-9.
- CONGREVE M, MURRAY CW, BLUNDELL TL: Structural biology and drug discovery. Drug Discov. Today. (2005) 10(13):895–907.
- KUBINYI H: Drug research: myths, hype and reality. Nat. Rev. Drug Disc. (2003) 2(8):665-668.
- BUTCHER EC: Can cell systems biology rescue drug discovery? Nature Rev. Drug Discov. (2005) 4(6):461-467.
- ERLANSON DA: Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol. (2006) 17:643-652.
- KITANO H: A robustness-based approach to systems-oriented drug design. Nature Rev. Drug Discov. (2007) 6(3):202-210.
- VAN DER GREEF J, MCBURNEY RN: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Rev. Drug Discov. (2005) 4(12):961-967.
- BLACK J: Drugs from emasculated hormones: the principle of syntopic antagonism. Science (1989) 245(4 August):486-493.
- GAMBARDELLA A: Science and Innovation:The US Pharmaceutical Industry during the 1980s. Cambridge University Press Cambridge (1995).
- CUSHMAN D, ONDETTI M: History of the design of specific inhibitors of angiotensin converting enzyme. Hypertension (1991) 17(4):589-592.
- NIGTHINGALE P, MARTIN P: The myth of the biotech revolution. Trends Biotechnol. (2004) 22(11):564-569.
- HARDY LW, MALIKAYIL A: The impact of structure-guided drug design in clinical agents. Curr. Drug Discov. (2003) (December):15-20.
- KUHN P, WILSON K, PATCH MG, STEVENS RC: The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. (2002) 6(5):704-710.
- LOCK E, ELLIS MK, GASKIN P et al.: From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J. Inher. Metab. Dis. (1998) 21:498-506.
- ROSENBLUM SB, HUYNH T, AFONSO A et al.: Discovery of 1-(4-fluorphenyl)-(3R)-[3-(4-fluorphenyl)-(3S)-hydroxypropyl]-4S-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, orally active inhibitor of cholesterol absorption. J. Med. Chem. (1998) 41:973-980.
- BUCHHEIT K, GAMSE R, GIGER R et al.: The serotonin 5-HT4 receptor. 1. design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. (1995) 38:2326-2330.
- KOPPITZ M, EIS K: Automated medicinal chemistry. Drug Discov. Today. (2006) 11(11/12):561-568.
Websites
- COCKBURN IM, HENDERSON R, STERN S: The diffusion of science driven drug discovery: organizational chance in pharmaceutical research. National Bureau of Economic Research Working Paper 7359. (1999), http://www.nber.org/papers/w7359.
- www.fda.gov/cder/present/galson/2007/2007CDERUpdateWCBPJan292007.pdf FDA website: “2007 CDER Update” (2007).
- http://www.fda.gov/cder/rdmt/NMECY2002.htm FDA website: “NMEs Approved in Calendar Year 2002” (2005).